IQVIA Holdings Inc. Reports Strong Second-Quarter 2026 Results
IQVIA Holdings Inc. (NYSE:IQV), a prominent player in clinical research services and healthcare intelligence, released its financial results for the second quarter of 2026 on July 28, showcasing significant growth across its business segments. The company’s performance exceeded expectations in revenue, Adjusted EBITDA, and Adjusted Diluted Earnings Per Share, reflecting a robust operational execution in a strengthening market environment.
1. Year-Over-Year Financial Highlights
In a strategic move, IQVIA implemented a new organizational model effective January 1, 2026, aimed at fostering collaboration and enhancing efficiency. This restructuring led to the reporting of financial results across two primary segments: Commercial Solutions and Research & Development Solutions (R&DS).
Second-Quarter 2026 Operating Results
Ari Bousbib, Chairman and CEO of IQVIA, expressed satisfaction with the company’s performance, stating, "R&D Solutions generated record-level net new bookings of over $3.1 billion and reported 7% organic revenue growth." He highlighted the double-digit growth in patient solutions and commercial engagement services within Commercial Solutions, along with a robust adoption of AI solutions.
For the second quarter, IQVIA reported:
- Total Revenue: $4,368 million, an increase of 8.7% year-over-year, or 8.5% at constant currency.
- Commercial Solutions Revenue: $1,793 million, up 8.6% reported and 8.4% at constant currency.
- R&D Solutions Revenue: $2,575 million, reflecting an 8.8% increase reported and 8.6% at constant currency.
Excluding reimbursed expenses, R&D Solutions revenue increased by 6.7% on a reported basis.
Bookings and Backlog
The company reported net new bookings of $3.15 billion for the second quarter, marking a 19% year-over-year increase and a book-to-bill ratio of 1.22x. Over the last twelve months, net new bookings totaled $11.3 billion, up 13% year-over-year. The contracted backlog for R&D Solutions stood at $34.2 billion as of June 30, 2026, with expectations of approximately $9.2 billion converting to revenue in the next twelve months, representing a 7.5% year-over-year growth.
Earnings Performance
The financial results for the second quarter included:
- GAAP Net Income: $256 million
- GAAP Diluted Earnings per Share: $1.53
- Adjusted EBITDA: $994 million, a 9.2% increase year-over-year.
- Adjusted Net Income: $527 million
- Adjusted Diluted Earnings per Share: $3.15, reflecting a 12.1% increase year-over-year.
2. First-Half 2026 Financial Overview
For the first half of 2026, IQVIA reported:
- Total Revenue: $8,519 million, an 8.6% increase reported and 7.3% at constant currency.
- Commercial Solutions Revenue: $3,547 million, up 10.1% reported and 8.5% at constant currency.
- R&D Solutions Revenue: $4,972 million, reflecting a 7.5% increase reported and 6.4% at constant currency.
- GAAP Net Income: $530 million
- GAAP Diluted Earnings per Share: $3.14
- Adjusted EBITDA: $1,926 million, up 7.4% year-over-year.
- Adjusted Net Income: $1,019 million
- Adjusted Diluted Earnings per Share: $6.04, up 9.8% year-over-year.
3. Financial Position and Share Repurchase
As of June 30, 2026, IQVIA's financial position included:
- Cash and Cash Equivalents: $1,909 million
- Debt: $15,999 million, leading to a net debt of $14,090 million.
- Net Leverage Ratio: 3.59x trailing twelve-month Adjusted EBITDA.
The operating cash flow for the second quarter was $558 million, a 26.0% year-over-year increase, while free cash flow was $360 million, up 23.3% year-over-year. During the second quarter, IQVIA repurchased $398 million of its common stock, bringing the total for the first half of 2026 to $950 million, with $2,819 million remaining under the share repurchase authorization.
4. Full-Year 2026 Guidance
In light of the strong performance and favorable market conditions, IQVIA has raised its full-year 2026 guidance:
- Revenue Guidance: Expected to be between $17,275 million and $17,475 million.
- Adjusted EBITDA Guidance: Projected between $4,000 million and $4,050 million.
- Adjusted Diluted Earnings per Share Guidance: Estimated to be between $12.80 and $13.00.
The revised guidance reflects increased expectations for organic revenue growth and contributions from mergers and acquisitions, despite some adverse impacts from foreign exchange rates.
5. Conclusion
IQVIA's second-quarter results for 2026 demonstrate strong operational execution and a positive trajectory in growth, driven by significant advancements in its Commercial and R&D Solutions segments. With a robust backlog and strategic enhancements in its organizational structure, IQVIA is poised for sustained momentum as it moves into the latter half of the year and beyond. Investors and analysts alike will be keenly watching the company’s performance in the upcoming quarters as it continues to navigate a dynamic market landscape.
